City Therapeutics Doses First Participant in Phase 1 Clinical Trial of CITY-RBP4
City Therapeutics has initiated its Phase 1 clinical trial for CITY-RBP4, an RNAi therapeutic candidate for Stargardt disease, by dosing the first participant.
Stocks · News reference
Jefferies Initiates Coverage of City Therapeutics with Buy Rating
Jefferies analyst Maury Raycroft initiated coverage on City Therapeutics with a buy rating and a $32 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Initiates Coverage of City Therapeutics with Outperform Rating
Oppenheimer has initiated coverage of City Therapeutics with an Outperform rating and a $46 price target.
Jefferies Initiates Coverage On City Therapeutics with Buy Rating, Announces Price Target of $32
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated coverage on Mentari, MongoDB, Comfort Systems and Ross Stores; City Therapeutics received an early-stage biotech rating.
Oppenheimer Initiates Coverage On City Therapeutics with Outperform Rating, Announces Price Target of $46
8-K filing — CITY THERAPEUTICS, INC. (CTY)
Filed: 2026-11-10 AccNo: 0001104659-26-124775 Size: 215 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits